Opinion|Videos|October 14, 2024

Sequencing Treatment and Optimizing Care in mCRPC: Insights From VISION and TheraP Trials

Key Takeaways

Neal Shore, MD, FACS, emphasizes the significance of the VISION and TheraP trials in supporting the FDA approval of Lutetium-177 for patients with mCRPC who have undergone androgen receptor inhibitor and taxane treatments, highlighting the role of PSMA PET imaging in treatment sequencing and patient selection.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME